Table 5 Baseline factors associated with symptoms at follow-up
From: Long-term cardiac pathology in individuals with mild initial COVID-19 illness
Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
Characteristic | OR1 | 95% CI1 | P value | OR1 | 95% CI1 | P value |
Age (years) | 1.02 | 1.00, 1.04 | 0.032 | – | – | – |
Gender (female) | 2.42 | 1.57, 3.76 | <0.001 | 2.26 | 1.42, 3.63 | <0.001 |
Heart rate (bpm) | 1.02 | 1.00, 1.04 | 0.036 | – | – | – |
Systolic BP (mmHg) | 1.00 | 0.98, 1.01 | 0.447 | – | – | – |
Diastolic BP (mmHg) | 1.01 | 0.99, 1.03 | 0.188 | – | – | – |
CRP (mg dl−1) | 1.36 | 0.47, 4.22 | 0.571 | – | – | – |
hs-TropT (pg ml−1) | 0.97 | 0.88, 1.06 | 0.452 | – | – | – |
NT-proBNP (pg ml−1) | 1.00 | 1.00, 1.01 | 0.128 | – | – | – |
LVEF (%) | 1.03 | 0.98, 1.08 | 0.231 | – | – | – |
GLS (%) | 0.99 | 0.90, 1.09 | 0.904 | – | – | – |
LV- EDVi (ml m−2) | 0.96 | 0.95, 0.98 | <0.001 | – | – | – |
LV mass index (g m−2) | 0.96 | 0.94, 0.98 | <0.001 | – | – | – |
RVEF (%) | 1.06 | 1.02, 1.10 | 0.003 | – | – | – |
Native T1 (10 ms) | 1.14 | 1.07, 1.20 | <0.001 | 1.13 | 1.06, 1.20 | <0.001 |
Native T2 (ms) | 1.22 | 1.07, 1.40 | 0.003 | |||
LGE (non-ischemic), present | 1.72 | 1.10, 2.70 | 0.016 | |||
Pericardial effusion, present | 1.38 | 0.86, 2.23 | 0.18 | |||
Pericardial enhancement | 1.39 | 0.90, 2.14 | 0.134 | |||
Time from diagnosis | 1.00 | 1.00, 1.00 | 0.37 | |||
